講題一:FORUM SELECTION IN HATCH-WAXMAN ACTIONS 報告人:邱冠勛/明富智財管理顧問有限公司資深顧問 《講 綱》 (1) Branded Drug (2) ANDA (3) Jurisdiction (4) Latest Case Law (5) Proposed Arguments
講題二:Navigating the Biosimilar Regulatory Framework 報告人:Kevin E. Warner/Winston & Strawn,LLP律師 《講 綱》 (1) Biosimilars vs. Generic Drugs (2) The "Patent Dance" (3) "Phase Two" Patents (4) Other Pending Biosimilar Cases (5) Recent U.S. Supreme Court Cases, Developments and Trends